Public Awareness about Medicine Information, Safety, and Adverse Drug Reaction (ADR) Reporting in Dammam, Saudi Arabia
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Venue
2.2. Target Population and Eligibility Criteria
2.3. Sampling Strategy and Data Collection
2.4. Sample Size Calculation
2.5. Questionnaire Development and Validation
2.6. Scoring of the Questionnaire
2.7. Data Analysis
2.8. Ethics Approval and Consent
3. Results
3.1. Medication Information
3.2. Medication Safety
3.3. Adverse Drug Reaction (ADR) Reporting Tendency
4. Discussion
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Inácio, P.; Cavaco, A.; Airaksinen, M. The value of patient reporting to the pharmacovigilance system: A systematic review. Br. J. Clin. Pharmacol. 2016, 83, 227–246. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Härmark, L.; Van Grootheest, A.C. Pharmacovigilance: Methods, recent developments and future perspectives. Eur. J. Clin. Pharmacol. 2008, 64, 743–752. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hazell, L.; Shakir, S.A. Under-Reporting of Adverse Drug Reactions. Drug Saf. 2006, 29, 385–396. [Google Scholar] [CrossRef] [PubMed]
- Silverman, S.L. From Randomized Controlled Trials to Observational Studies. Am. J. Med. 2009, 122, 114–120. [Google Scholar] [CrossRef] [PubMed]
- Alves, C.; Macedo, A.F.; Marques, F.B. Sources of information used by regulatory agencies on the generation of drug safety alerts. Eur. J. Clin. Pharmacol. 2013, 69, 2083–2094. [Google Scholar] [CrossRef]
- Pal, S.N.; Duncombe, C.; Falzon, D.; Olsson, S. WHO Strategy for Collecting Safety Data in Public Health Programmes: Complementing Spontaneous Reporting Systems. Drug Saf. 2013, 36, 75–81. [Google Scholar] [CrossRef] [Green Version]
- WHO Library Cataloguing-in-Publication Data. Safety Monitoring of Medical Products: Reporting System for the General Public. 2012. Available online: https://www.who.int/medicines/areas/quality_safety/safety_efficacy/ConsumerReporting.pdf?ua=1 (accessed on 2 February 2020).
- Scurti, V.; Romero, M.; Tognoni, G. A plea for a more epidemiological and patient-oriented pharmacovigilance. Eur. J. Clin. Pharmacol. 2011, 68, 11–19. [Google Scholar] [CrossRef]
- Uppsala Monitoring Center. Uppsala Reports 45. 2009. Available online: https://www.who-umc.org/media/164350/ur45_07_no_shadow_.pdf (accessed on 2 February 2020).
- Alharf, A.; Alqahtani, N.; Saeed, G.; Alshahrani, A.; Alshahrani, M.; AlJasser, N.; Alquwaizani, M.; Bawazir, S. Saudi Vigilance Program: Challenges and lessons learned. Saudi Pharm. J. 2018, 26, 388–395. [Google Scholar] [CrossRef]
- Uppsala Monitoring Center. Uppsala Reports 47. 2009. Available online: https://www.who-umc.org/media/164375/ur47.pdf (accessed on 2 February 2020).
- Robertson, J.; Newby, D.A. Low awareness of adverse drug reaction reporting systems: A consumer survey. Med. J. Aust. 2013, 199, 684–686. [Google Scholar] [CrossRef] [Green Version]
- Tandon, V.R.; Mahajan, V.; Khajuria, V.; Gillani, Z. Under-reporting of adverse drug reactions: A challenge for pharmacovigilance in India. Indian J. Pharmacol. 2015, 47, 65–71. [Google Scholar] [CrossRef]
- Matos, C.; Van Hunsel, F.; Joaquim, J. Are consumers ready to take part in the Pharmacovigilance System?—A Portuguese preliminary study concerning ADR reporting. Eur. J. Clin. Pharmacol. 2015, 71, 883–890. [Google Scholar] [CrossRef] [PubMed]
- Petrovic, M.; van der Cammen, T.; Onder, G. Recognition of Adverse Drug Events in Older Hospitalized Medical Patients. Eur. J. Clin. Pharmacol. 2013, 69, 75–85. [Google Scholar] [CrossRef] [Green Version]
- Narumol, J.; Arunrot, P.; Krska, J. Survey of patients’ experiences and their certainty of suspected adverse drug reactions. Int. J. Clin. Pharm. 2015, 37, 168–174. [Google Scholar] [CrossRef]
- Survey System. Sample Size Calculation. 2020. Available online: https://www.surveysystem.com/sscalc.htm. (accessed on 27 January 2020).
- Global Media Insight. Saudi Arabia Population. 2020. Available online: https://www.globalmediainsight.com/blog/saudi-arabia-population-statistics/ (accessed on 27 January 2020).
- Sales, I.; Aljadhey, H.; Albogami, Y.; Mahmoud, M.A. Public awareness and perception toward Adverse Drug Reactions reporting in Riyadh, Saudi Arabia. Saudi Pharm. J. 2017, 25, 868–872. [Google Scholar] [CrossRef] [PubMed]
- Salgueiro-Vázquez, M.E.; Gurruchaga, C.; Jimeno, F.J.; Martin, L.; Arias, L.H.M.; Manso, G. What can we learn from the public’s understanding of drug information and safety? A population survey. Int. J. Pharm. Pract. 2018, 27, 96–104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lawshe, C.H. A Quantitative Approach to Content Validity. Pers. Psychol. 1975, 28, 563–575. [Google Scholar] [CrossRef]
- Alshayban, D.M.; Naqvi, A.A.; Islam, A.; Almaskeen, M.; Almulla, A.; Alali, M.; AlQaroos, A.; Raafat, M.; Iqbal, M.S.; Haseeb, A. Patient Satisfaction and Their Willingness to Pay for a Pharmacist Counseling Session in Hospital and Community Pharmacies in Saudi Healthcare Settings. Front. Pharmacol. 2020, 11, 138. [Google Scholar] [CrossRef] [Green Version]
- Alamri, S.A.; Al Jaizani, R.A.; Naqvi, A.A.; Al Ghamdi, M.S. Assessment of Drug Information Service in Public and Private Sector Tertiary Care Hospitals in the Eastern Province of Saudi Arabia. Pharmacy 2017, 5, 37. [Google Scholar] [CrossRef] [Green Version]
- Lewis, M.A.; Butterfield, R.M. Social Control in Marital Relationships: Effect of One’s Partner on Health Behaviors. J. Appl. Soc. Psychol. 2007, 37, 298–319. [Google Scholar] [CrossRef]
- Dimatteo, M.R. Social Support and Patient Adherence to Medical Treatment: A Meta-Analysis. Health Psychol. 2004, 23, 207–218. [Google Scholar] [CrossRef] [Green Version]
- Krska, J.; Morecroft, C.W. Patients’ Use of Information about Medicine Side Effects in Relation to Experiences of Suspected Adverse Drug Reactions: A Cross-Sectional Survey in Medical In-Patients. Drug Saf. 2013, 36, 673–680. [Google Scholar] [CrossRef] [PubMed]
- Nathan, J.P.; Zerilli, T.; Cicero, L.A.; Rosenberg, J.M. Patients’ Use and Perception of Medication Information Leaflets. Ann. Pharmacother. 2007, 41, 777–782. [Google Scholar] [CrossRef] [PubMed]
- Raynor, D.K.; Silcock, J.; Knapp, P.; Edmondson, H. How do patients use medicine information leaflets in the UK? Int. J. Pharm. Pract. 2007, 15, 209–218. [Google Scholar] [CrossRef]
- Carrigan, N.; Raynor, D.K.; Knapp, P. Adequacy of patient information on adverse effects: An assessment of patient information leaflets in the UK. Drug Saf. 2008, 31, 305–312. [Google Scholar] [CrossRef]
- Bawazir, S.A. Attitude of community pharmacists in Saudi Arabia towards adverse drug reaction reporting. Saudi. Pharm. J. 2006, 14, 75–83. [Google Scholar]
- Al-Hazmi, N.; Il, N. Attitude and Awareness of Adverse Drug Reaction Reporting by Health Professionals in Seven Hospitals in the Holy City of Makkah, Kingdom of Saudi Arabia. J. Clin. Trials 2013, 3, 2–5. [Google Scholar] [CrossRef] [Green Version]
- Mahmoud, M.A.; Alswaida, Y.; Alshammari, T.; Khan, T.M.; Alrasheedy, A.; Hassali, M.A.; Aljadhey, H. Community pharmacists’ knowledge, behaviors and experiences about adverse drug reaction reporting in Saudi Arabia. Saudi Pharm. J. 2013, 22, 411–418. [Google Scholar] [CrossRef] [Green Version]
Panelist | Items | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | |
1. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
2. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
3. | ✓ | x | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | x | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
4. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
5. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | x | ✓ | ✓ | ✓ | ✓ | ✓ |
6. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
7. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | x | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
8. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | x |
Item # In Questionnaire | Section 1: Knowledge of Medicine on a Scale of 0 to 6. (0 = Poor Knowledge, 6 = Good Knowledge) | Score |
---|---|---|
4. | When you have to take a drug, do you know what it is for? | |
Yes | 2 | |
No | 0 | |
Sometimes | 1 | |
I do not know | 0 | |
5. | When you have to take a drug, do you know when and with what frequency you have to take it? | |
Yes | 2 | |
No | 0 | |
Sometimes | 1 | |
I do not know | 0 | |
6. | When you have to take a drug, do you know how long you have to take it for? | |
Yes | 2 | |
No | 0 | |
Sometimes | 1 | |
I do not know | 0 | |
Section 2: Knowledge Regarding Medication Safety on a Scale of 0 to 10. (0 = Poor Knowledge, 10 = Good Knowledge) | ||
7. | Do you read the patient information leaflet for medicines? | |
Always | 2 | |
Sometimes | 1 | |
Never | 0 | |
8. | Do you find the patient information leaflet difficult to understand? | |
Yes | 0 | |
No | 2 | |
Sometimes | 1 | |
10. | What does an adverse drug reaction (ADR) mean? | |
Any effect from the medication | 0 | |
Unexpected reaction after taking the normal dose | 2 | |
Expected reaction after taking the normal dose | 0 | |
I do not know | 0 | |
11. | Do you ask or search about your medication’s ADR? | |
Always | 2 | |
Sometimes | 1 | |
Rarely | 0.5 | |
Never | 0 | |
12. | Which of the following resources do you use to search or ask about ADR? | |
Asking the physician | 2 | |
Asking the pharmacist | 2 | |
Internet | 2 | |
Patient Information Leaflet (PIL) | 2 | |
I do not search about it. | 0 | |
Section 3: Tendency to Report a Suspected ADR on a Scale of 0 to 8. (0 = Lowest, 8 = Highest) | ||
13. | In your opinion who should be responsible for reporting a suspected ADR from medications? | |
Health care professional | 0 | |
Consumers | 2 | |
All of the above | 2 | |
14. | Have you heard about Saudi National Pharmacovigilance Center (NPC)? | |
Yes | 2 | |
No | 0 | |
16. | If you have experienced an ADR before, who did you report to from the following? | |
Health Practitioner | 2 | |
Saudi National Pharmacovigilance Center (NPC) | 2 | |
Did not report it | 0 | |
Did not experience | 2 | |
17. | Do you know that consumer can directly report suspected ADR through Saudi vigilance program (NPC)? | |
Yes | 2 | |
No | 0 |
Variables | Frequency (n) | Percent (%) |
---|---|---|
Age | ||
18–30 | 498 | 54.4 |
31–45 | 257 | 28.1 |
46–64 | 152 | 16.6 |
Older than 65 | 8 | 0.9 |
Gender | ||
Female | 602 | 65.8 |
Male | 313 | 34.2 |
Level of education | ||
Middle School | 16 | 1.7 |
High school | 261 | 28.5 |
Diploma | 106 | 11.6 |
Bachelors | 486 | 53.1 |
Higher education | 46 | 5 |
Occupation | ||
Health sector employee | 64 | 7 |
Non-health sector employee | 315 | 34.4 |
Un-employed/home maker | 151 | 16.5 |
Health Student | 231 | 25.2 |
Non-Health Student | 154 | 16.8 |
Social Status | ||
Single | 410 | 44.8 |
Married | 505 | 55.2 |
Characteristics | Frequency (n) | Percent (%) |
---|---|---|
In the last three months, have you taken any drug by medical prescription? | ||
Yes | 525 | 57.9 |
No | 377 | 42.1 |
In the last three months, have you taken any drug not by medical prescription? | ||
Yes | 483 | 52.8 |
No | 416 | 45.5 |
I do not know | 16 | 1.7 |
If yes, who recommended it? | ||
Pharmacist | 187 | 20.4 |
Health practitioner | 50 | 5.5 |
Friends and family | 83 | 9.1 |
Apothecary | 5 | 0.5 |
Social Media | 12 | 1.3 |
Myself | 228 | 24.9 |
When you have to take a drug, do you know what it is for? | ||
Yes | 790 | 86.3 |
No | 12 | 1.3 |
Sometimes | 112 | 12.2 |
I do not know | 1 | 0.1 |
When you have to take a drug, do you know when and with what frequency you have to take it? | ||
Yes | 773 | 84.5 |
No | 30 | 3.3 |
Sometimes | 110 | 12 |
I do not know | 2 | 0.2 |
When you have to take a drug, do you know how long you have to take it for? | ||
Yes | 677 | 74 |
No | 74 | 8.1 |
Sometimes | 150 | 16.4 |
I do not know | 14 | 1.5 |
Characteristics | Frequency (n) | Percent (%) |
---|---|---|
Do you read the patient information leaflet (PIL) for medicines? 1 | ||
Always | 394 | 43.1 |
Sometimes | 454 | 49.6 |
Never | 67 | 7.3 |
Do you find the patient information leaflet (PIL) difficult to understand? | ||
Yes | 66 | 7.2 |
No | 524 | 57.3 |
Sometimes | 325 | 35.5 |
Which part of the patient information leaflet (PIL) do you read? | ||
All | 484 | 52.9 |
Indication | 180 | 19.7 |
Dose and instruction | 112 | 12.2 |
Side effects | 139 | 15.2 |
What does an ADR mean? 2 | ||
Any effect from the medication | 332 | 36.3 |
Unexpected reaction after taking the normal dose | 340 | 37.2 |
Expected reaction after taking the normal dose | 222 | 24.3 |
I do not know | 21 | 2.3 |
Do you ask or search about your medication’s ADR? | ||
Always | 185 | 20.2 |
Sometimes | 372 | 40.7 |
Rarely | 209 | 22.8 |
Never | 149 | 16.3 |
Which of the following resource do you use to search or ask about ADR? | ||
Asking the physician | 195 | 21.3 |
Asking the pharmacist | 121 | 13.2 |
Internet | 218 | 23.8 |
Patient information leaflet (PIL) | 267 | 29.2 |
I did not search about it. | 114 | 12.5 |
Characteristics | Frequency (n) | Percent (%) |
---|---|---|
In your opinion, who should be responsible for reporting possible ADR from medications? | ||
Healthcare professionals (HCPs) | 357 | 39 |
Consumers | 21 | 2.3 |
All of the above | 537 | 58.7 |
Have you ever experienced an ADR? | ||
Yes | 146 | 16 |
No | 619 | 67.7 |
I do not know | 150 | 16.4 |
If you have experienced an ADR before who did you report to? | ||
Health Practitioner | 74 | 8.1 |
Saudi National Pharmacovigilance Center (SNPC) | 1 | 0.1 |
Did not report it | 71 | 7.8 |
Did not experience | 769 | 84 |
Have you heard about Saudi National Pharmacovigilance Center (SNPC)? | ||
Yes | 82 | 9 |
No | 833 | 91 |
Do you know that consumer can directly report suspected ADR through Saudi vigilance program in NPC? | ||
Yes | 88 | 9.6 |
No | 827 | 90.4 |
Do you agree that this reporting of suspected ADR should be available for public? | ||
Yes | 852 | 93.1 |
No | 46 | 5 |
I do not know | 17 | 1.9 |
In your opinion, should consumers receive more information about ADR reporting. | ||
Yes | 828 | 90.5 |
No | 9 | 1 |
I do not know | 78 | 8.5 |
Variables | Knowledge of Medicine (K1) | Knowledge about Medication Safety (K2) | Tendency to Report Suspected ADR (T1) | |||
---|---|---|---|---|---|---|
Mean (SD) | MD (95% CI) | Mean (SD) | MD (95% CI) | Mean (SD) | MD (95% CI) | |
Age | ||||||
Up to 45 years | 5.43 (1.11) | −0.24 (−0.42, −0.05) ** | 6.02 (1.74) | 0.43 (0.14, 0.73) ** | 3.46 (1.62) | 0.12 (−0.15, 0.39) ns |
More than 45 years | 5.66 (0.89) | 5.59 (1.64) | 3.34 (1.30) | |||
Gender | ||||||
Female | 5.52 (1.02) | 0.14 (−0.01, 0.29) ns | 6.14 (1.78) | 0.57 (0.34, 0.79) *** | 3.53 (1.67) | 0.27 (0.07, 0.47) ** |
Male | 5.37 (1.17) | 5.57 (1.57) | 3.26 (1.35) | |||
Level of education | ||||||
Up to high school | 5.42 (1.09) | −0.07 (−0.23, 0.08) ns | 5.88 (1.67) | −0.09 (−0.34, 0.15) ns | 3.39 (1.39) | −0.06 (−0.27, 0.15) ns |
Higher education | 5.49 (1.07) | 5.97 (1.76) | 3.45 (1.65) | |||
Employment Status | ||||||
Employed | 5.61 (0.93) | 0.24 (0.11, 0.38) *** | 5.83 (1.65) | −0.19 (−0.42, 0.04) ns | 3.43 (1.49) | 0.01 (−0.21, 0.20) ns |
Un-employed | 5.37 (1.15) | 6.02 (1.79) | 3.44 (1.63) | |||
Social Status | ||||||
Single | 5.19 (1.28) | −0.49 (−0.63, −0.35) *** | 5.80 (1.81) | −0.25 (−0.48, −0.03) * | 3.42 (1.63) | −0.03 (−0.24, 0.16) ns |
Married | 5.68 (0.81) | 6.05 (1.66) | 3.45 (1.52) |
Variables | Model for Knowledge of Medicine (K1) £ | Model for Knowledge about Medication Safety (K2) ¥ | ||||
---|---|---|---|---|---|---|
Coefficient (β) and (95% CI of β) | p-Value | VIF | Coefficient (β) and (95% CI of β) | p-Value | Variance Inflation Factor | |
Age (≤45 years vs. >45 years) | −0.003 (−0.21, 0.19) | 0.928 | 1.23 | 0.011 (−0.17, 0.23) | 0.756 | 1.20 |
Gender (Female vs. Male) | --- | --- | --- | −0.093 (−0.37, −0.07) | 0.005 | 1.04 |
Employment Status (Employed vs. Un-employed) | 0.007 (−0.15, 0.18) | 0.850 | 1.43 | --- | --- | --- |
Social Status (Single vs. Married) | 0.233 (0.34, 0.67) | p < 0.001 | 1.45 | 0.235 (0.36, 0.66) | p < 0.001 | 1.18 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Islam, M.A.; Al-Karasneh, A.F.; Naqvi, A.A.; AlShayban, D.M.; Al-Hayek, F.; Al-Badrani, S.; Al-Salem, R.; Ghori, S.A. Public Awareness about Medicine Information, Safety, and Adverse Drug Reaction (ADR) Reporting in Dammam, Saudi Arabia. Pharmacy 2020, 8, 222. https://doi.org/10.3390/pharmacy8040222
Islam MA, Al-Karasneh AF, Naqvi AA, AlShayban DM, Al-Hayek F, Al-Badrani S, Al-Salem R, Ghori SA. Public Awareness about Medicine Information, Safety, and Adverse Drug Reaction (ADR) Reporting in Dammam, Saudi Arabia. Pharmacy. 2020; 8(4):222. https://doi.org/10.3390/pharmacy8040222
Chicago/Turabian StyleIslam, Md. Ashraful, Aseel Fuad Al-Karasneh, Atta Abbas Naqvi, Dhfer Mahdi AlShayban, Fatimah Al-Hayek, Sarah Al-Badrani, Raghad Al-Salem, and Syed Azizullah Ghori. 2020. "Public Awareness about Medicine Information, Safety, and Adverse Drug Reaction (ADR) Reporting in Dammam, Saudi Arabia" Pharmacy 8, no. 4: 222. https://doi.org/10.3390/pharmacy8040222
APA StyleIslam, M. A., Al-Karasneh, A. F., Naqvi, A. A., AlShayban, D. M., Al-Hayek, F., Al-Badrani, S., Al-Salem, R., & Ghori, S. A. (2020). Public Awareness about Medicine Information, Safety, and Adverse Drug Reaction (ADR) Reporting in Dammam, Saudi Arabia. Pharmacy, 8(4), 222. https://doi.org/10.3390/pharmacy8040222